Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

6.2K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
6.2K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

4.3K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

670
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
670
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

9.6K
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
9.6K
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

4
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
4
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

6
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
6

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism.

Bone research·2026
Same author

Clinical profile, treatment practices, and complications in chronic hypoparathyroidism in a Middle Eastern cohort.

Journal of the Endocrine Society·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Sex- and Pubertal Stage-Specific Bone Microarchitecture and Strength in Adolescents With Type 1 Diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same author

Journal of Bone and Mineral Research (JBMR) 40th anniversary celebration the third decade (part 1).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Vitamin D in Gut and Systemic Immune Tolerance and in Infections' Risk: An International Evidence-Based Consensus Statement.

Reviews in endocrine & metabolic disorders·2026

Related Experiment Video

Updated: Apr 18, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.5K

Parathyroid hormone therapy for hypoparathyroidism.

Natalie E Cusano1, Mishaela R Rubin1, John P Bilezikian1

  • 1Department of Medicine, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, 630 West 168th Street, PH 8W-864, New York, NY 10032, USA.

Best Practice & Research. Clinical Endocrinology & Metabolism
|January 25, 2015
PubMed
Summary

This review discusses parathyroid hormone (PTH) replacement therapy for hypoparathyroidism, a rare endocrine disorder. PTH therapy offers a potential treatment for hypocalcemia and related symptoms unmet by conventional calcium and vitamin D.

Keywords:
PTH(1-34)PTH(1-84)hypoparathyroidismparathyroid hormoneteriparatide

More Related Videos

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

15.5K
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

5.3K

Related Experiment Videos

Last Updated: Apr 18, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.5K
Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

15.5K
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

5.3K

Area of Science:

  • Endocrinology
  • Metabolic Bone Disease
  • Rare Diseases

Background:

  • Hypoparathyroidism is characterized by low calcium and insufficient parathyroid hormone (PTH).
  • It is an orphan disease with limited therapeutic options beyond calcium and vitamin D.
  • Conventional therapies struggle to fully manage symptoms and improve quality of life.

Purpose of the Study:

  • To review the current status of parathyroid hormone (PTH) replacement therapy for hypoparathyroidism.
  • To evaluate the use of full-length PTH(1-84) and truncated PTH(1-34) in treating this condition.
  • To highlight the potential of PTH therapy to address unmet needs in hypoparathyroidism management.

Main Methods:

  • Review of existing literature on hypoparathyroidism and PTH replacement therapies.
  • Analysis of studies utilizing PTH(1-84) and PTH(1-34) for therapeutic purposes.
  • Discussion of the efficacy and limitations of current and emerging treatments.

Main Results:

  • Parathyroid hormone (PTH) therapy, using PTH(1-84) or PTH(1-34), is being explored as a treatment for hypoparathyroidism.
  • PTH replacement therapy may address aspects of the disease not managed by conventional calcium and vitamin D supplementation.
  • Challenges remain in optimizing PTH therapy for improved patient outcomes and quality of life.

Conclusions:

  • Parathyroid hormone (PTH) replacement therapy represents a promising approach for hypoparathyroidism.
  • Further research and clinical application of PTH(1-84) and PTH(1-34) are warranted.
  • PTH therapy has the potential to significantly improve the management of this rare endocrine disorder.